Role of BCL2-associated athanogene 1 in differential sensitivity of human endothelial cells to glucocorticoids

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 5, 2013, Pages 1046-1055

  Mata Greenwood, Eugenia ^a   Stewart, John M ^a   Steinhorn, Robin H ^b   Pearce, William J ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

coagulation; endothelium; glucocorticoids; sensitivity

Indexed keywords

BAG 1 PROTEIN; CYCLOHEXIMIDE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PROCOAGULANT;

ARTICLE; CELL DIFFERENTIATION; DRUG HALF LIFE; DRUG SENSITIVITY; ENDOTHELIUM CELL; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; TRANSACTIVATION; UMBILICAL VEIN ENDOTHELIAL CELL;

CELLS, CULTURED; DEXAMETHASONE; DNA-BINDING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTION FACTORS; UBIQUITINATION;

EID: 84876285422     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301247     Document Type: Article

References (63)

1. Barnes PJ. Anti-infammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998;94:557-572.
2. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
3. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545-559.
4. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2:1-12.
5. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16:505-511.
6. Girod JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovasc Res. 2004;64:217-226.
7. Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glu-cocorticoid metabolism in cardiovascular disease. Br J Pharmacol. 2009;156:689-712.
8. van Zaane B, Nur E, Squizzato A, Gerdes VE, Büller HR, Dekkers OM, Brandjes DP. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fbrinolytic factors. J Thromb Haemost. 2010;8:2483-2493.
9. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Förstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA. 1999;96:13357-13362.
10. Lou YK, Wen C, Li M, Adams DJ, Wang MX, Yang F, Morris BJ, Whitworth JA. Decreased renal expression of nitric oxide synthase iso-forms in adrenocorticotropin-induced and corticosterone-induced hypertension. Hypertension. 2001;37:1164-1170.
11. Belvisi MG. Regulation of infammatory cell function by corticosteroids. Proc Am Thorac Soc. 2004;1:207-214.
12. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Prednisolone augments superoxide formation in porcine pulmonary artery endothelial cells through differential effects on the expression of nitric oxide synthase and NADPH oxidase. Br J Pharmacol. 2005;145:688-697.
13. Yamamoto Y, Ishizu A, Ikeda H, Otsuka N, Yoshiki T. Dexamethasone increased plasminogen activator inhibitor-1 expression on human umbilical vein endothelial cells: an additive effect to tumor necrosis factor-alpha. Pathobiology. 2004;71:295-301.
14. Kimura H, Li X, Torii K, Okada T, Kamiyama K, Mikami D, Takahashi N, Yoshida H. Dexamethasone enhances basal and TNF-alpha-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11beta-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells. Nephrol Dial Transplant. 2009;24:1759-1765.
15. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344.
16. Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB. Glucocorticoid receptor physiology. Rev Endocr Metab Disord. 2007;8:321-330.
17. Kino T. Tissue glucocorticoid sensitivity: beyond stochastic regulation on the diverse actions of glucocorticoids. Horm Metab Res. 2007;39:420-424.
18. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev. 1996;17:245-261.
19. Whorwood CB, Donovan SJ, Wood PJ, Phillips DI. Regulation of gluco-corticoid receptor alpha and beta isoforms and type I 11beta-hydroxys- teroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab. 2001;86:2296-2308.
20. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinfammatory cyto-kines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA. 2001;98:6865-6870.
21. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117:522-543.
22. Pratt WB, Morishima Y, Murphy M, Harrelll M. Chaperoning of glucocor-ticoid receptors. Handb Exp Pharmacol. 2006; 172:111-138.
23. Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol. 2007;275:2-12.
24. Schmidt U, Wochnik GM, Rosenhagen MC, Young JC, Hartl FU, Holsboer F, Rein T. Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the glucocorticoid receptor. J Biol Chem. 2003;278:4926-4931.
25. Takayama S, Reed JC. Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol. 2001;3:E237-E241.
26. Cato AC, Mink S. BAG-1 family of cochaperones in the modulation of nuclear receptor action. J Steroid Biochem Mol Biol. 2001;78:379-388.
27. Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc. 2004;1:247-254.
28. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol. 2007;275:13-29.
29. Bruzdzinski CJ, Johnson MR, Goble CA, Winograd SS, Gelehrter TD. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identifcation of cis-acting regulatory elements. Mol Endocrinol. 1993;7:1169-1177.
30. Clark AR. Anti-infammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol. 2007;275:79-97.
31. Revollo JR, Cidlowski JA. Mechanisms generating diversity in glucocorti-coid receptor signaling. Ann N Y Acad Sci. 2009;1179:167-178.
32. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005;18:331-342.
33. Biddie SC, Conway-Campbell BL, Lightman SL. Dynamic regulation of glucocorticoid signalling in health and disease. Rheumatology (Oxford). 2012;51:403-412.
34. Niu N, Manickam V, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW, Wieben ED, Schaid DJ, Wang L. Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomics. J Clin Endocrinol Metab. 2009;94:3072-3084.
35. Pedersen KB, Geng CD, Vedeckis WV. Three mechanisms are involved in glucocorticoid receptor autoregulation in a human T-lymphoblast cell line. Biochemistry. 2004;43:10851-10858.
36. Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann N Y Acad Sci. 2009;1179:153-166.
37. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem. 2001;276:42714-42721.
38. van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA. 1988;85:5525-5529.
39. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, infammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1:1575-1579.
40. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost. 2004;91:861-872.
41. Levy AS, Chung JC, Kroetsch JT, Rush JW. Nitric oxide and coronary vascular endothelium adaptations in hypertension. Vasc Health Risk Manag. 2009;5:1075-1087.
42. Liu Y, Mladinov D, Pietrusz JL, Usa K, Liang M. Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res. 2009;81:140-147.
43. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J. 2007;21:265-273.
44. Newton K, Matsumoto ML, Wertz IE, et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specifc antibodies. Cell. 2008;134:668-678.
45. Liman J, Faida L, Dohm CP, Reed JC, Bähr M, Kermer P. Subcellular distribution affects BAG1 function. Brain Res. 2008;1198:21-26.
46. Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ, Miyashita T, Yamada M, Reed JC. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res. 1998;58:3116-3131.
47. Gehring U. Biological activities of HAP46/BAG-1. The HAP46/BAG-1 protein: regulator of HSP70 chaperones, DNA-binding protein and stimulator of transcription. EMBO Rep. 2004;5:148-153.
48. Kanelakis KC, Morishima Y, Dittmar KD, Galigniana MD, Takayama S, Reed JC, Pratt WB. Differential effects of the hsp70-binding protein BAG-1 on glucocorticoid receptor folding by the hsp90-based chaperone machinery. J Biol Chem. 1999;274:34134-34140.
49. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 1995;80:279-284.
50. Nollen EA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci. 2002;115:2809-2816.
51. Song J, Takeda M, Morimoto RI. Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth. Nat Cell Biol. 2001;3:276-282.
52. Kermer P, Digicaylioglu MH, Kaul M, Zapata JM, Krajewska M, Stenner-Liewen F, Takayama S, Krajewski S, Lipton SA, Reed JC. BAG1 over-expression in brain protects against stroke. Brain Pathol. 2003;13:495-506.
53. Townsend PA, Cutress RI, Carroll CJ, Lawrence KM, Scarabelli TM, Packham G, Stephanou A, Latchman DS. BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome. J Biol Chem. 2004;279:20723-20728.
54. Liman J, Ganesan S, Dohm CP, Krajewski S, Reed JC, Bähr M, Wouters FS, Kermer P. Interaction of BAG1 and Hsp70 mediates neuroprotectivity and increases chaperone activity. Mol Cell Biol. 2005;25:3715-3725.
55. Frebel K, Wiese S, Funk N, Pühringer D, Sendtner M. Differential modulation of neurite growth by the S-and the L-forms of bag1, a co-chaperone of Hsp70. Neurodegener Dis. 2007;4:261-269.
56. Liu HY, Wang ZM, Bai Y, Wang M, Li Y, Wei S, Zhou QH, Chen J. Different BAG-1 isoforms have distinct functions in modulating chemo-therapeutic-induced apoptosis in breast cancer cells. Acta Pharmacol Sin. 2009;30:235-241.
57. Bray PJ, Du B, Mejia VM, Hao SC, Deutsch E, Fu C, Wilson RC, Hanauske-Abel H, McCaffrey TA. Glucocorticoid resistance caused by reduced expression of the glucocorticoid receptor in cells from human vascular lesions. Arterioscler Thromb Vasc Biol. 1999;19:1180-1189.
58. Willis MS, Patterson C. Hold me tight: Role of the heat shock protein family of chaperones in cardiac disease. Circulation. 2010;122:1740-1751.
59. Xu Q, Metzler B, Jahangiri M, Mandal K. Molecular chaperones and heat shock proteins in atherosclerosis. Am J Physiol Heart Circ Physiol. 2012;302:H506-H514.
60. He M, Guo H, Yang X, Zhang X, Zhou L, Cheng L, Zeng H, Hu FB, Tanguay RM, Wu T. Functional SNPs in HSPA1A gene predict risk of coronary heart disease. PLoS ONE. 2009;4:e4851.
61. Almeida MB, do Nascimento JL, Herculano AM, Crespo-López ME. Molecular chaperones: toward new therapeutic tools. Biomed Pharmacother. 2011;65:239-243.
62. Witchel SF, DeFranco DB. Mechanisms of disease: regulation of gluco-corticoid and receptor levels-impact on the metabolic syndrome. Nat Clin Pract Endocrinol Metab. 2006;2:621-631.
63. Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci. 2009;1179:179-198.Current address for R.H.S.: Department of Pediatrics, UC Davis Children's Hospital, Sacramento, CA.